Studies in other cancer types, including serous ovarian cancers and endometrial carcinomas, also showed that CCNE1 amplification or Cyclin E overexpression was associated with more aggressive tumor features, but was not an independent predictor factor of survival47–49. Here, CCNE1 is linked to cancer.